Novel therapies for multiple myeloma

Blood Reviews

Volumn 16, Issue 3, 2002, Pages 167-174

  Ryoo, Joan J ^a   Emmitt Cole, Craig ^b,c   Anderson, Kenneth C ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Arsenic trioxide; Cytokines; Immunomodulatory drugs; Multiple myeloma; Proteasome inhibitors; Thalidomide

Indexed keywords

2 METHOXYESTRADIOL; 2 METHOXYESTRADIOL 2; AE 941; ARSENIC TRIOXIDE; BORTEZOMIB; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; GAG PROTEIN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; MITOXANTRONE; PROTEASOME INHIBITOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; 2-METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYSTEINE PROTEINASE; DRUG DERIVATIVE; ENZYME INHIBITOR; ESTRADIOL; MULTIENZYME COMPLEX; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEASOME; SHARK CARTILAGE EXTRACT AE 941; TISSUE EXTRACT;

CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; META ANALYSIS; MULTIPLE MYELOMA; NEUROPATHY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; DRUG ANTAGONISM; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ARSENICALS; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; ESTRADIOL; HUMANS; MULTIENZYME COMPLEXES; MULTIPLE MYELOMA; OXIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; THALIDOMIDE; TISSUE EXTRACTS;

EID: 0036729515     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(02)00009-7     Document Type: Review

References (98)

1. Multiple myeloma: Increasing evidence for a multistep transformation process
2. Novel therapeutic targets in multiple myeloma
3. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
4. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
5. The biology of multiple myeloma
6. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM)
7. Immunomodulating IL-6 activity by murine monoclonal antibodies
8. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
9. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies
10. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells
11. Interleukin-6 anti-sense oligonucleotides inhibit the growth of human myeloma cell lines
12. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases
13. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
14. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells
15. Role of Interleukin-6 in the pathogenesis of multiple myeloma
16. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion
17. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications
18. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB
19. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
20. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
21. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: Therapeutic applications
22. CD40 ligand triggered interleukin-6 secretion in multiple myeloma
23. Antiangiogenic therapy
24. Bone marrow angiogenesis and progression in multiple myeloma
25. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies
26. Prognostic value of bone marrow angiogenesis in multiple myeloma
27. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
28. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
29. Targeted therapy for multiple myeloma
30. How proteolysis drives the cell cycle
31. The proteasome inhibitor PS-341 in cancer therapy
32. Proteasome inhibitors: A novel class of potent and effective antitumor agents
33. Proteasome inhibitors as potential novel anticancer agents
34. Proteasome inhibition: A new strategy in cancer treatment
35. p53-dependent induction of apoptosis by proteasome inhibitors
36. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
37. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
38. The ubiquitin proteasome pathway is required for processing the N F-κBI precursor protein and the activation of NF-κB
39. Suppression of TNF-α-induced apoptosis by NF-κB
40. An essential role for NF-κB in preventing TNF-α-induced cell death
41. TNF-α cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
42. Proteasome inhibition: A novel mechanism to combat asthma
43. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
44. Proteasome inhibitor PS-341 is effective as an anti-angiogenic agent in the treatment of human pancreatic carcinoma via the inhibition of NF-κB and subsequent inhibition of vascular endothelial growth factor production
45. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
46. Proteasome inhibitor P5-341inhibits human multiple myeloma cell growth in a murine model
47. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
48. Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis
49. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells
50. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade
51. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by Bcl-2
52. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 in under NK-κB control
53. NF-κB antiapoptosis: Induction of TRAF-1 and TRAF-2 and cIAP2 to suppress caspase-8 activation
54. Proteasome inhibitor PS-341 markedly enhances sensitivity of MM cells to chemotherapeutic agents and overcomes chemo-resistance through inhibition of the NF-κB pathway
55. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone, in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy
56. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
57. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
58. Bone marrow angiogenesis in patients after stem cell transplantation for multiple myeloma
59. Thalidomide is an inhibitor of angiogenesis
60. Thalidomide - A revival story
61. Antitumor activity of thalidomide in refractory multiple myeloma
62. Free radical mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
63. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
64. Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines
65. Characterization of adhesion molecules on human myeloma cell lines
66. The development of a model for the homing of multiple myeloma cells to human bone marrow
67. Expression of vascular endothelial growth factor and its receptor in hematological malignancies
68. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma
69. H1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
70. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
71. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
72. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
73. Tumor cell expression of CD 59 is associated with resistance to CD20 serotherapy in B cell malignancies
74. A phase I trial of oral CC-5013, an immunomodulatory thalidomide derivative, in patients with relapsed and refractory multiple myeloma
75. Arsenicals in hematologic cancers
76. Arsenic trioxide: An emerging therapy for multiple myeloma
77. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
78. Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies
79. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis
80. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
81. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment
82. Arsenic compounds induce apoptosis in multiple myeloma (MM), activate pro-caspase-3 but do not affect bcl-2 family members
83. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism
84. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells
85. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
86. 3) on myeloma cells
87. Co-biomodulation with arsenic trioxide in multiple myeloma
88. Inhibition of tumor angiogenesis mediated by cartilage
89. Shark cartilage extracts as antiangiogenic agents: Smart drinks or bitter pills?
90. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials
91. AE-941 (Neovastat): A novel multifunctional antiangiogenic compound
92. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound
93. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model
94. Antiangiogenic and antimetastatic properties of neovastat (AE-941), an orally active extract derived from cartilage tissue
95. The antiangiogenic agent Neovastat (AE-941) inhibits VEGF-mediated biological effects
96. The antiangiogenic agent Neovastat (AE-941) induced endothelial cell apoptosis
97. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site
98. 2-Methoxyestradiol (2ME2) overcome drug resistance in multiple myeloma cells